Shineco Partners with BICC to Advance RWA Ecosystem and Cell Asset Redeemability

Shineco Inc. Partners with BICC for Innovative RWA Ecosystem Growth

On August 27, 2025, Shineco Inc., traded under NASDAQ as SISI, announced a strategic partnership with Singapore-based BICC Pte Ltd, signaling a transformative step in the realm of the RWA (Real-World Assets) ecosystem. This collaboration aims to enhance the implementation and redeemability of ‘on-chain cell assets’ across various institutions, moving the industry from mere technical integration to practical, real-world applications.

Shineco has been at the forefront of developing induced pluripotent stem cell (iPSC) technology platforms, and this partnership aligns perfectly with its ongoing efforts. Just prior to this agreement, the company made significant strides by establishing its Cell Digital Division and entering into a partnership with Plus Me Limited to manage and market cell assets on-chain. Additionally, Shineco acquired a 51% stake in Xi'an Dong'ao Health Management Co., Ltd. to bolster its health management and stem cell storage capabilities. These foundational steps set the stage for the cutting-edge digital application of cellular assets.

Under the new cooperative framework with BICC, Plus Me will implement full-lifecycle digital management for Shineco’s compliant mesenchymal stem cells on the Ethereum mainnet. This entails the generation of 'digital identities' and the issuance of Cell Reimbursement Vouchers in compliance with ERC-1400/ERC-20 standards. Users who hold these vouchers can redeem them at configured BICC service points, establishing a vast network of cross-enterprise services.

To optimize the offline aspects of this collaboration, Shineco has created an innovative 'storage + reinfusion' network, drawing on its acquisition of Xi'an Dong'ao Health, which specializes in stem cell storage and health management services. BICC will leverage its extensive distribution network, comprising over 3,000 sales representatives, to act as interconnected nodes within this network. This partnership addresses significant inefficiencies in traditional procedures, streamlining the validation of vouchers and the access to cell therapy services at BICC’s Asian service centers.

Furthermore, BICC's array of clinically validated solutions—including wound-healing treatments, serum-free media, and cell banking services—will enhance Shineco’s extracellular vesicle-derived products. The capabilities of both organizations will be synergistically integrated into the blockchain asset valuation system, strengthening the technical endorsement of on-chain assets.

In clarifying their respective roles, Shineco will emphasize quality control and the standardization of offline networks, while BICC will focus on user engagement and scenario integration. Together, they plan to work alongside technical partners to fine-tune compliance tools and ensure all endeavors adhere to local regulations and internal guidelines. Shineco will guarantee cell quality, while Plus Me oversees on-chain compliance, and BICC contributes its scientists and medical resources to standardize the evolving landscape of cell assets.

The CEO of Shineco, Jennifer Zhan, expressed her enthusiasm about this collaboration, stating, "The partnership with BICC tightly integrates standards with practical scenarios, allowing us to explore verifiable application paths within a compliant framework. Shineco is evolving from a singular technical service provider to a comprehensive global infrastructure for the cell economy. We look forward to welcoming more companies into our expanding ecosystem and will keep stakeholders updated on our progress."

About BICC Pte Ltd

Founded in 2024, BICC is an innovative biotechnology conglomerate that combines top-tier scientists and medical experts focused on stem cell therapies and AI-driven solutions. With offices strategically located across Asia in China, Thailand, and Singapore, BICC utilizes proprietary technologies, including patented serum-free media and clinical therapies, impacting personalized cell banking and overall health solutions.

About Shineco, Inc.

Shineco, Inc. is dedicated to the mission of enhancing quality of life through safe and innovative health and medical products. Its core operations revolve around the platform technologies of iPSC and extracellular vesicle-derived products, further solidifying its commitment to healthy living.

This latest partnership not only symbolizes a new era in biotechnological collaboration but underscores the rising importance of blockchain technology in democratizing access to advanced medical solutions. By merging strengths and resources, Shineco and BICC are poised to redefine the standards of medical asset management and utilization in the burgeoning sector of regenerative medicine.